Envista Holdings Co. (NYSE:NVST) Receives $20.65 Consensus Target Price from Brokerages

Shares of Envista Holdings Co. (NYSE:NVST) have received a consensus recommendation of “Hold” from the sixteen research firms that are presently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, eleven have issued a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $20.65.

Several brokerages have issued reports on NVST. Wells Fargo & Company initiated coverage on Envista in a research note on Tuesday, October 8th. They set an “equal weight” rating and a $20.00 price objective on the stock. Stifel Nicolaus raised their price objective on Envista from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Robert W. Baird boosted their target price on shares of Envista from $17.00 to $22.00 and gave the company a “neutral” rating in a research note on Thursday, October 31st. Leerink Partners upgraded shares of Envista from an “underperform” rating to a “market perform” rating and raised their price target for the stock from $16.00 to $23.00 in a research report on Thursday, October 31st. Finally, Mizuho assumed coverage on shares of Envista in a report on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 price target for the company.

Institutional Trading of Envista

Several large investors have recently added to or reduced their stakes in NVST. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Envista in the third quarter worth $31,000. GAMMA Investing LLC lifted its holdings in Envista by 69.8% in the third quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock worth $35,000 after purchasing an additional 726 shares during the period. Huntington National Bank grew its position in Envista by 97.8% in the 3rd quarter. Huntington National Bank now owns 1,919 shares of the company’s stock valued at $38,000 after buying an additional 949 shares in the last quarter. Blue Trust Inc. grew its position in Envista by 69.7% in the 3rd quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock valued at $39,000 after buying an additional 804 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its stake in Envista by 50.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock valued at $43,000 after buying an additional 728 shares during the period.

Envista Stock Down 0.4 %

NVST stock opened at $19.03 on Monday. The company has a market capitalization of $3.28 billion, a P/E ratio of -2.45, a PEG ratio of 2.71 and a beta of 1.31. The firm has a 50 day simple moving average of $20.25 and a 200-day simple moving average of $18.50. The company has a current ratio of 2.08, a quick ratio of 1.77 and a debt-to-equity ratio of 0.42. Envista has a twelve month low of $15.15 and a twelve month high of $25.64.

Envista (NYSE:NVST) last released its earnings results on Wednesday, October 30th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.03. Envista had a negative net margin of 53.42% and a positive return on equity of 3.76%. The company had revenue of $601.00 million during the quarter, compared to the consensus estimate of $590.34 million. During the same quarter in the previous year, the firm earned $0.43 EPS. The company’s revenue was down 4.8% on a year-over-year basis. On average, equities research analysts predict that Envista will post 0.72 earnings per share for the current fiscal year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.